Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Opioid

or Phenethylamine

or Selective 5HT2A inverse agonist (with weaker 5HT2C inverse agonism)

Use the filters below to narrow your results.

Codeine (2)

None (37) · (multiple, generic dominant) (1) · Alfenta (1) · Darvon (1) · Demerol (1) · Dilaudid (1) · Duragesic (1) · Heroin (1) · Krokodil (1) · Nexus, Eroxan (historical, late-1980s through mid-1990s) (1) · Nubain (1) · Nucynta (1) · Nuplazid (1) · O-DSMT (1) · Opana (1) · Stablon (1) · Stadol (1) · Sufenta (1) · Talwin (1) · Ultiva (1) · Vicodin (1)

5-HT2A agonist (12) · 5-HT2A agonist; long duration (1) · 5-HT2A agonist; MAO inhibitor (1) · 5-HT2A agonist; milder than other 2C-x (1) · 5-HT2A partial agonist (1) · Active metabolite of tramadol; mu-opioid agonist (1) · Extremely potent 5-HT2A agonist; vasoconstrictor (1) · Extremely potent 5-HT2A agonist; very long duration (1) · Extremely potent mu-opioid receptor agonist (1) · Highly potent mu-opioid receptor agonist (1) · Kappa agonist; mu antagonist (1) · Kappa agonist; mu partial agonist (1) · Kappa agonist; mu partial agonist/antagonist (1) · Mitragynine/7-hydroxymitragynine; mu-opioid partial agonist (1) · Mu-opioid agonist; modulates glutamate AMPA receptors (1) · Mu-opioid agonist; norepinephrine reuptake inhibitor (1) · Mu-opioid receptor agonist (4) · Mu-opioid receptor agonist; fentanyl analogue (1) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Mu-opioid receptor agonist; sodium channel blocker (1) · Mu/kappa/delta agonist; NMDA antagonist (1) · Opioid receptor partial agonist/antagonist; toxic alkaloid (1) · Partial mu-opioid receptor agonist; alpha-2 agonist (1) · Phosphodiesterase inhibitor; calcium channel blocker (1) · Potent 5-HT2A agonist (5) · Potent 5-HT2A agonist; no oral activity (1) · Potent 5-HT2A agonist; very long duration (1) · Potent mu-opioid receptor agonist (6) · Prodrug of morphine; mu-opioid receptor agonist (1) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) · Selective inverse agonist at 5HT2A receptors with weaker activity at 5HT2C. Has no significant dopamine D2 affinity, unique among approved antipsychotics. Inverse agonism (rather than antagonism) reduces constitutive 5HT2A receptor activity below baseline. (1) · Selective mu-opioid receptor agonist (1) · Ultra-short-acting mu-opioid agonist (1) · Very potent 5-HT2A agonist; long duration (1)

None (55) · Hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Investigational for psychosis in other dementias and as augmentation for depression. (1) · Mild to moderate pain; cough suppression (low-dose). (1)

None (55) · 34 mg PO once daily (1) · Adult: 15–60 mg every 4 hours as needed. (1)

None (55) · 10 mg, 34 mg capsules/tablets (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (55) · 34 mg/d (1) · 360 mg/day (1)

None (54) · insufflated (1) · Oral (2) · PO (only formulation marketed in the US). (1) · PR (1)

None (54) · 30–60 min (PO) (1) · 45-75 min (oral) (1) · Benefit over weeks of dosing (1)

None (54) · 4-8 h (1) · 4–6 hours (1) · Daily dosing (1)

None (54) · 2.5–3 hours (1) · Not well characterized (1) · ~57 hours (parent), ~200 h (active metabolite) (1)

None (54) · Not characterized; oral dosing once daily (1) · Not well characterized (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)

None (54) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Limited data; avoid (1) · Not established (1)

None (54) · Rx. FDA black-box warning for increased mortality in elderly patients with dementia-related psychosis (class warning shared with all antipsychotics) (1) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:DEA Schedule I|Schedule I]] (United States) (1)